Lode-Star Mining Past Earnings Performance
Past criteria checks 0/6
Lode-Star Mining has been growing earnings at an average annual rate of 21.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually.
Key information
21.3%
Earnings growth rate
14.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lode-Star Mining makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | 0 | 0 | 0 |
30 Sep 23 | 0 | 0 | 0 | 0 |
30 Jun 23 | 0 | 0 | 0 | 0 |
31 Mar 23 | 0 | 2 | 0 | 0 |
31 Dec 22 | 0 | 2 | 0 | 0 |
30 Sep 22 | 0 | 0 | 0 | 0 |
30 Jun 22 | 0 | 0 | 0 | 0 |
31 Mar 22 | 0 | -2 | 0 | 0 |
31 Dec 21 | 0 | -3 | 0 | 0 |
30 Sep 21 | 0 | 0 | 0 | 0 |
30 Jun 21 | 0 | 0 | 0 | 0 |
31 Mar 21 | 0 | 0 | 0 | 0 |
31 Dec 20 | 0 | 0 | 0 | 0 |
30 Sep 20 | 0 | 0 | 0 | 0 |
30 Jun 20 | 0 | 0 | 0 | 0 |
31 Mar 20 | 0 | 0 | 0 | 0 |
31 Dec 19 | 0 | 0 | 0 | 0 |
30 Sep 19 | 0 | 0 | 0 | 0 |
30 Jun 19 | 0 | 0 | 0 | 0 |
31 Mar 19 | 0 | 0 | 0 | 0 |
31 Dec 18 | 0 | 0 | 0 | 0 |
30 Sep 18 | 0 | 0 | 0 | 0 |
30 Jun 18 | 0 | 0 | 0 | 0 |
31 Mar 18 | 0 | -1 | 0 | 0 |
31 Dec 17 | 0 | -1 | 1 | 0 |
30 Sep 17 | 0 | -1 | 0 | 0 |
30 Jun 17 | 0 | -1 | 0 | 0 |
31 Mar 17 | 0 | 0 | 0 | 0 |
31 Dec 16 | 0 | 0 | 0 | 0 |
30 Sep 16 | 0 | 0 | 0 | 0 |
30 Jun 16 | 0 | 0 | 0 | 0 |
31 Mar 16 | 0 | 0 | 0 | 0 |
31 Dec 15 | 0 | 0 | 0 | 0 |
30 Sep 15 | 0 | 0 | 0 | 0 |
30 Jun 15 | 0 | 0 | 0 | 0 |
31 Mar 15 | 0 | 0 | 0 | 0 |
31 Dec 14 | 0 | 0 | 0 | 0 |
30 Sep 14 | 0 | 0 | 0 | 0 |
Quality Earnings: LSMG is currently unprofitable.
Growing Profit Margin: LSMG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LSMG is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare LSMG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LSMG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: LSMG's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.